Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-70 in NMIBC
NCT04752722Phase 2Recruiting
- Sponsor
- enGene
- Start
- Apr 2021
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Acoustic/Optical: Sonoporation, laser photoporation, Gene Silencing
- Countries
- 10
01
Overview
A Phase 2 trial of detalimogene voraplasmid in non-muscle-invasive bladder cancer (NMIBC), sponsored by enGene. Started Apr 2021; status: recruiting.
02
Drugs
detalimogene voraplasmid
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04752722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752722.